Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...
Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury: Carlsbad, California Thursday, February 13, 2025, 14:00 Hrs [IST] Lineage Cell Therapeutic ...
Hosted on MSN6d
Charlotte said goodbye to her fiancé for the day. Hours later, she received a devastating call.June 18, 2024 started like any other day for Charlotte Gordon and her fiancé, Johnny Konings. Johnny made his morning coffee ...
A 59-year-old female healthcare worker presented with features of acute-onset non-compressive myelopathy with a sensory level at T10 segment along with high ... infectious diseases spinal cord This ...
Changes were also observed in the spinal cord, manifesting as distinct alterations in the ... factor (BDNF), nerve growth factor (NGF), and VEGF in C57BL/6 mice with T10 contusion injury (Huang et al.
More than 15 million people worldwide are living with spinal cord injury (SCI), which can affect their sensory and motor ...
A neurosurgeon and a neuroscientist discover promising new ways to help people with spinal cord injuries walk again ...
Lineage Cell Therapeutics (LCTX) announced that the Company has initiated the DOSED clinical study. The DOSED study will evaluate the safety ...
Her injuries have left her with paralysis in her right leg, weakness in her left leg and some degree of paralysis in both ...
UW Medicine is unveiling an FDA-approved spinal cord therapy in an effort to offer new hope for paralyzed patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback